EP4376822A4 - Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen - Google Patents

Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen

Info

Publication number
EP4376822A4
EP4376822A4 EP22850545.9A EP22850545A EP4376822A4 EP 4376822 A4 EP4376822 A4 EP 4376822A4 EP 22850545 A EP22850545 A EP 22850545A EP 4376822 A4 EP4376822 A4 EP 4376822A4
Authority
EP
European Patent Office
Prior art keywords
acylfulvenes
cancer
combinations
treatment
parp inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22850545.9A
Other languages
English (en)
French (fr)
Other versions
EP4376822A1 (de
Inventor
Aditya Kulkarni
Kishor Bhatia
Jianli Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Lantern Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantern Pharma Inc filed Critical Lantern Pharma Inc
Publication of EP4376822A1 publication Critical patent/EP4376822A1/de
Publication of EP4376822A4 publication Critical patent/EP4376822A4/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP22850545.9A 2021-07-29 2022-07-29 Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen Pending EP4376822A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227260P 2021-07-29 2021-07-29
US202263365995P 2022-06-07 2022-06-07
PCT/US2022/074314 WO2023010119A1 (en) 2021-07-29 2022-07-29 Treating cancers with combinations of parp inhibitor and acylfulvenes

Publications (2)

Publication Number Publication Date
EP4376822A1 EP4376822A1 (de) 2024-06-05
EP4376822A4 true EP4376822A4 (de) 2025-09-17

Family

ID=85087343

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22850545.9A Pending EP4376822A4 (de) 2021-07-29 2022-07-29 Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen

Country Status (5)

Country Link
EP (1) EP4376822A4 (de)
JP (1) JP2024528725A (de)
CA (1) CA3227306A1 (de)
MX (1) MX2024001314A (de)
WO (1) WO2023010119A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4554683A2 (de) * 2022-07-15 2025-05-21 Lantern Pharma Inc. Verfahren zur behandlung von brustkrebs und parp-resistentem brustkrebs
AU2024233068A1 (en) * 2023-03-09 2025-10-23 Lantern Pharma Inc. Method for treating renal cell carcinoma or cancer
AU2024327731A1 (en) * 2023-08-23 2026-03-05 Lantern Pharma Inc. Treating liver cancers with hydroxyureamethyl acylfulvene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4989648B2 (ja) * 2005-08-03 2012-08-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗癌剤として有用なイルジン類似体
FI3386546T3 (fi) * 2015-12-07 2024-12-05 General Oncology Inc Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla
CA3116552A1 (en) * 2018-10-14 2020-04-23 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KULKARNI A ET AL: "LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects", CANCER RESEARCH, vol. 81, no. 13_Suppl, 1 July 2021 (2021-07-01), XP093300530, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-1249 *
See also references of WO2023010119A1 *
UMESH KATHAD ET AL: "A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications", BMC BIOINFORMATICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 22, no. 1, 2 March 2021 (2021-03-02), pages 1 - 23, XP021287233, DOI: 10.1186/S12859-021-04040-8 *

Also Published As

Publication number Publication date
MX2024001314A (es) 2024-04-30
CA3227306A1 (en) 2023-02-02
EP4376822A1 (de) 2024-06-05
JP2024528725A (ja) 2024-07-30
WO2023010119A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
EP4326720A4 (de) Parp1-inhibitoren und verwendungen davon
EP3600382A4 (de) Behandlung von krebs mit cas-endonuklease-komplexen
EP3585817A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4412716A4 (de) Kombinationen aus kras-g12d-inhibitoren und pi3ka-inhibitoren und zugehörige behandlungsverfahren
EP3612222A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4125846A4 (de) Pyrazolylpropanamidverbindungen und verwendungen davon zur behandlung von prostatakrebs
EP4355749A4 (de) Tricyclische parp1-inhibitoren und verwendungen davon
EP3592346A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4376821A4 (de) Behandlung von krebs mit kombinationen aus spironolacton und acylfulvenen
EP3528834A4 (de) Behandlung von krebs mit einer kombination aus einem pd-1-antagonisten und einem il-27-inhibitor
EP3873613A4 (de) 5-halouracil-modifizierte mikrornas und deren verwendung in der behandlung von krebs
EP4412720A4 (de) Kombinationen aus kras-g12d-inhibitoren und irinotecan und zugehörige behandlungsverfahren
EP4232052A4 (de) Kombination aus radioimmuntherapie und cd47-blockade bei der behandlung von krebs
IL283899A (en) Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
EP3820492A4 (de) Apmv und ihre verwendungen zur behandlung von krebs
EP3877422A4 (de) Therapeutische dosierpläne zur behandlung von krebs mit eribulin und selektiven cdk4/6-inhibitorkombinationen
EP4203979C0 (de) Behandlung von krebs und autoimmun- und entzündungskrankheiten
EP3600329A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP4412613A4 (de) Verfahren zur behandlung von krebs und tumoren
EP3532289A4 (de) Polyoxometallatkomplexe und verwendungen in der behandlung von krebs
EP3585398A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP3570837A4 (de) Zusammensetzungen und verfahren zur behandlung von androgenunabhängigem krebs
EP3826623A4 (de) Zusammensetzungen und verfahren zur behandlung von mit pcsk9-expression charakterisiertem krebs
EP4301356A4 (de) Behandlung von brustkrebs mit amcenestratant und palbociclib
EP4247406A4 (de) Behandlung von enpp1-mangel und abcc6-mangel

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250819

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/122 20060101AFI20250812BHEP

Ipc: C07C 35/22 20060101ALI20250812BHEP

Ipc: C07C 49/727 20060101ALI20250812BHEP

Ipc: A61P 35/00 20060101ALI20250812BHEP

Ipc: A61K 31/166 20060101ALI20250812BHEP

Ipc: A61K 31/4184 20060101ALI20250812BHEP

Ipc: A61K 31/454 20060101ALI20250812BHEP

Ipc: A61K 31/5025 20060101ALI20250812BHEP

Ipc: A61K 31/55 20060101ALI20250812BHEP

Ipc: A61K 31/502 20060101ALI20250812BHEP

Ipc: A61K 9/00 20060101ALI20250812BHEP

Ipc: A61K 31/337 20060101ALI20250812BHEP

Ipc: A61K 33/243 20190101ALI20250812BHEP